# OnCo record combi-d (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/combi-d/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "combi-d", "NCT01584648" ;
  schema:name "COMBI-d"@en ;
  schema:description "COMBI-d showed that adding a MEK inhibitor to a BRAF inhibitor delays progression and lengthens life in BRAF-mutant melanoma, and that the pairing causes fewer of the skin cancers that BRAF inhibitors alone provoke."@en ;
  schema:url <https://onco.cc/trials/combi-d/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01584648>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1406037>, <https://doi.org/10.1016/S0140-6736(15)60898-4>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1904059> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/melanoma/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/mek/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/gsk/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:people <https://onco.cc/people/georgina-long/>, <https://onco.cc/people/keith-flaherty/> .